Prices are updated after-hours
  Health Technology Gastrointestinal

nasdaq:APEN Apollo Endosurgery, Inc.

APEN | $10.0 0.75% 1.7M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-53.84% volume)
Earnings Calendar: 2023-05-02
Market Cap: $ 579,719,190
http://apolloendo.com
 Sec Filling | Patents | 217 employees


Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, OverStitch Sx Endoscopic Suturing System, and Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas; inadvertent perforation of the GI tract; tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon; the treatment of swallowing disorders; esophageal stent fixation and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.
gastrointestinal   endoscopy   treatment  

add to watch list Paper trade email alert is off

nasdaq:ALBO Albireo Pharma, Inc.

ALBO | $44.15 -0.23% 0.39% 1.2M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-02-28
Market Cap: $ 913,961,644
http://www.albireopharma.com
 Sec Filling | Patents | 55 employees


(US) Albireo Pharma, Inc. engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. It pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.
gastrointestinal   liver   liver disease   treatment   odevixibat  

add to watch list Paper trade email alert is off

nasdaq:MTCR Metacrine, Inc.

MTCR | $0.5814 -5.14% 84K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (4.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-50.69% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 24,749,916
http://www.metacrine.com
 Sec Filling | Patents | 35 employees


Metacrine, Inc. is a clinical-stage biopharmaceutical company that engages in the discovery and development of differentiated therapies for patients with liver and gastrointestinal diseases. Its farnesoid X receptor, or FXR, is central to modulating liver and GI diseases. The company was founded by Ronald M. Evans, Richard A. Heyman, and Michael Downes in 2014 and is headquartered in San Diego, CA.
gastrointestinal   liver  

add to watch list Paper trade email alert is off

nasdaq:PLXP PLx Pharma Inc.

PLXP | $0.087 -4.6% 50M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar: 2023-04-17
Market Cap: $ 2,534,979
http://www.plxpharma.com
 Sec Filling | Patents | 12 employees


(US) PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.
gastrointestinal  

add to watch list Paper trade email alert is off

nasdaq:BMRA Biomerica, Inc.

BMRA | $0.7459 -1.86% -1.89% 35K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-27.0% 1m) (-57.8% 1y) (-3.9% 2d) (-3.9% 3d) (-5.2% 7d) (-36.03% volume)
Earnings Calendar: 2022-10-13
Market Cap: $ 12,547,266
http://www.biomerica.com
 Sec Filling | Patents | 45 employees


Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other Foreign. The company was founded in September 1971 and is headquartered in Irvine, CA.
gastrointestinal   diabetes   diabetic   food   diagnostics  

add to watch list Paper trade email alert is off

nyse:BSX Boston Scientific Corporation

BSX | $67.33 -0.13% -0.31% 7M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-0.3% 1m) (31.7% 1y) (-0.1% 2d) (-0.1% 3d) (-0.2% 7d) (17.14% volume)
Earnings Calendar: 2024-01-31
Market Cap: $ 98,779,548,566
http://www.bostonscientific.com
 Sec Filling | Patents | 36000 employees


Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.
cardiovascular   heart   gastrointestinal   endoscopy   eletrical  

add to watch list Paper trade email alert is off

nasdaq:EDSA Edesa Biotech, Inc.

EDSA | $4.47 2.52% 2.46% 2.4K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (8.8% 1m) (312.0% 1y) (2.1% 2d) (2.1% 3d) (7.0% 7d) (77.37% volume)
Earnings Calendar: 2022-12-07
Market Cap: $ 14,375,377
http://www.edesabiotech.com
 Sec Filling | Patents | 10 employees


Edesa Biotech, Inc. is a biopharmaceutical company. It focuses on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company product candidate, EB01, is a sPLA2 inhibitor for the topical treatment of chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. Edesa Biotech was founded in 2007 and is headquartered in Markham, Canada.
dermatitis   gastrointestinal   acne   treatment  

add to watch list Paper trade email alert is off

nasdaq:DCPH Deciphera Pharmaceuticals, Inc.

DCPH | $14.69 3.23% 3.13% 390K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-5.4% 1m) (-0.3% 1y) (0.0% 2d) (0.0% 3d) (-1.5% 7d) (33.0% volume)
Earnings Calendar: 2024-02-07
Market Cap: $ 1,186,952,911
http://www.deciphera.com
 Sec Filling | Patents | 258 employees


Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.
cancer   gastrointestinal   tumor cells   t-cell   msa   treatment   ceiling  

add to watch list Paper trade email alert is off

nyse:ENZ Enzo Biochem, Inc.

ENZ | $1.09 -3.54% 0.0% 260K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-9.9% 1m) (-57.8% 1y) (-3.5% 2d) (-3.5% 3d) (-6.0% 7d) (27.12% volume)
Earnings Calendar:
Market Cap: $ 55,836,050
http://www.enzo.com
 Sec Filling | Patents | 448 employees


Enzo Biochem, Inc. engages in the development, manufacture and sale of technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. It operates through the following segments: Enzo Clinical Laboratory Services, Enzo Life Sciences Products, and Enzo Therapeutics. The Enzo Clinical Laboratory Services segment includes clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences Products segment manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. The Enzo Therapeutics segment develops multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.
covid test   gastrointestinal   urea   metabolic  

add to watch list Paper trade email alert is off

nasdaq:EVOK Evoke Pharma, Inc.

EVOK | $0.493 2.97% 2.88% 1.9K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-20.3% 1m) (-75.8% 1y) (0.0% 2d) (0.0% 3d) (-1.1% 7d) (-92.36% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 4,179,556
http://www.evokepharma.com
 Sec Filling | Patents | 5 employees


Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.
diabetes   gastrointestinal   diabetic   women   treatment  

Drugs
GIMOTI (METOCLOPRAMIDE HYDROCHLORIDE)

add to watch list Paper trade email alert is off

nasdaq:GLAXF GLAXOSMITHKLINE PLC

GLAXF | News | $20.2 -14.18% 510 twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-3.8% 1m) (10.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-50.0% volume)
Earnings Calendar:
Market Cap: $ 81,384,717,745
http://gsk.com
 Sec Filling | Patents | n/a employees


(GB) GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
brands   hepatitis   infectious disease   respiratory   vaccine   battery   batteries   pain relief   gastrointestinal   skin   pets   influenza  

add to watch list Paper trade email alert is off

nyse:GSK GlaxoSmithKline PLC

GSK | News | $39.75 1.22% 0.0% 1.6M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-6.2% 1m) (8.3% 1y) (0.0% 2d) (0.4% 3d) (-1.9% 7d) (-49.39% volume)
Earnings Calendar:
Market Cap: $ 82,379,488,927
http://gsk.com
 Sec Filling | Patents | 99437 employees


GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
skin   vaccine   batteries   battery   respiratory   nutrition   gastrointestinal   infectious disease   pets   hepatitis   influenza   brands   pain relief  

add to watch list Paper trade email alert is off

nasdaq:IPCIF Intellipharmaceutics International Inc.

IPCIF | $0.07 -29.49% 4.2K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-26.3% 1m) (9.1% 1y) (0.0% 2d) (0.0% 3d) (-55.6% 7d) (-37.58% volume)
Earnings Calendar:
Market Cap: $ 2,316,487
http://www.intellipharmaceutics.com
 Sec Filling | Patents | n/a employees


(CA) Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of pharmaceuticals in the areas of neurology, cardiovascular, gastrointestinal tract, diabetes and pain. The company was founded by Isa Odidi and Amina Odidi in 1998 and is headquartered in Toronto, Canada.
gastrointestinal   urea   diabetic   diabetes   cardiovascular  

add to watch list Paper trade email alert is off

nasdaq:JAGX Jaguar Health, Inc.

JAGX | $0.158 -10.79% -12.09% 30M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (102.5% 1m) (-71.9% 1y) (-11.1% 2d) (0.0% 3d) (34.7% 7d) (-52.77% volume)
Earnings Calendar: 2023-11-14
Market Cap: $ 43,642,169
http://www.jaguar.health
 Sec Filling | Patents | 29 employees


(US) Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
diarrhea   hiv   gastrointestinal   animals  

add to watch list Paper trade email alert is off

nyse:MDT Medtronic plc

MDT | $79.48 0.37% -0.29% 6.7M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-4.7% 1m) (-7.3% 1y) (0.0% 2d) (0.5% 3d) (-1.9% 7d) (19.8% volume)
Earnings Calendar: 2024-02-20
Market Cap: $ 105,535,335,400
http://www.medtronic.com
 Sec Filling | Patents | 90000 employees


(US) Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, and Renal divisions. The Restorative Therapies Group contains Spine, Brain, Specialty Therapies, and Pain Therapies divisions. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland.
respiratory   heart   gastrointestinal   diabetes   diabetic   renal  

add to watch list Paper trade email alert is off

nasdaq:PHAT Phathom Pharmaceuticals, Inc.

PHAT | $8.98 -5.27% -5.57% 590K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-2.1% 1m) (-15.2% 1y) (0.0% 2d) (-8.5% 3d) (-10.5% 7d) (38.46% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 525,546,427
http://www.phathompharma.com
 Sec Filling | Patents | 25 employees


Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. It focuses on its vonoprazan product, an oral small molecule potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.
gastrointestinal   treatment  

add to watch list Paper trade email alert is off

nasdaq:RDHL Redhill Biopharma Ltd.

RDHL | $0.4519 7.39% 6.88% 330K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-11.4% 1m) (-83.6% 1y) (0.0% 2d) (15.4% 3d) (11.3% 7d) (38.98% volume)
Earnings Calendar:
Market Cap: $ 398,458
http://www.redhillbio.com
 Sec Filling | Patents | 182 employees


(IL) RedHill Biopharma Ltd. is a biopharmaceutical company focusing on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company’s subsidiary in the United States. The Research & Development segment includes all activities related to the research and development of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.
gastrointestinal   israel   urea   treatment  

add to watch list Paper trade email alert is off

nasdaq:RYTM Rhythm Pharmaceuticals, Inc.

RYTM A | $37.975 -0.35% -0.36% 620K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-6.5% 1m) (82.7% 1y) (-0.3% 2d) (-1.1% 3d) (-5.2% 7d) (40.3% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 2,283,835,298
http://www.rhythmtx.com
 Sec Filling | Patents | 70 employees


(US) Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
gastrointestinal   car-t   genetic   mc4r agonist   treatment  

add to watch list Paper trade email alert is off

nyse:STE STERIS plc

STE | $199.51 -0.65% 0.0% 530K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-12.1% 1m) (6.6% 1y) (0.0% 2d) (-0.4% 3d) (-0.8% 7d) (-51.96% volume)
Earnings Calendar: 2024-02-07
Market Cap: $ 19,714,388,123
http://www.steris.com
 Sec Filling | Patents | 13000 employees


STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services. This segment offers its products and services to acute care hospitals, ambulatory surgery centers, and GI clinics. The Healthcare Specialty Services segment provides solutions and managed services, such as instrument and endoscope repair and maintenance solutions; custom process improvement consulting services; and outsourced instrument sterile processing services to acute care hospitals and other healthcare settings. The Life Sciences segment offers formulated cleaning chemistries, barrier products, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. The Applied Sterilization Technologies segment provides contract sterilization services through a network of approximately 50 contract sterilization and laboratory facilities.The company was founded on December 22, 2016 and is headquartered in Dublin, Ireland.
hydrogen   gastrointestinal   endoscopy   injection  

add to watch list Paper trade email alert is off

nasdaq:TARA Protara Therapeutics, Inc.

TARA | $2.62 -4.73% -4.96% 210K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-32.3% 1m) (-24.8% 1y) (-4.0% 2d) (-3.3% 3d) (-7.0% 7d) (-13.88% volume)
Earnings Calendar: 2024-03-06
Market Cap: $ 29,956,653
http://www.protaratx.com
 Sec Filling | Patents | 12 employees


(US) Protara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman in 2017 and is headquartered in New York, NY.
gastrointestinal   metabolic   treatment  

add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlist
Gainers vs Losers
67% 33%

Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M twitter stocktwits trandingview |
Finance
EGOX | $0.0515 43.06% 30.1% 330M twitter stocktwits trandingview |

OLB 4 | $0.33 -14.95% 25.53% 840K twitter stocktwits trandingview |
Technology Services
NVFY | $2.77 31.28% 23.83% 33M twitter stocktwits trandingview |
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M twitter stocktwits trandingview |
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M twitter stocktwits trandingview |
Distribution Services
INSG | $3.03 25.21% 20.13% 330K twitter stocktwits trandingview |
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K twitter stocktwits trandingview |
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M twitter stocktwits trandingview |

ASNS | $0.828 21.75% 17.86% 18K twitter stocktwits trandingview |

Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M twitter stocktwits trandingview |
n/a
 | 23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M twitter stocktwits trandingview |
Finance
 | 22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K twitter stocktwits trandingview |
Health Technology
 | 22:30
BCDA P 2750 | $0.377 -1.4% 97K twitter stocktwits trandingview |
Health Technology
 | 22:00
RMCF | $3.67 3.38% 3.27% 11K twitter stocktwits trandingview |
Consumer Non-Durables
 | 20:10
12 months watchlist earnings calendar